Clinical trials: Vascular Endothelial Growth Factor, active
Acute Kidney Injury, Cardiac Surgery Associated - Acute Kidney Injury
Perioperative Role Of Vascular Endothelial Growth Factor In Cardiac Surgery-associated Acute Kidney Injury
The goal of this prospective observational study is to find out whether the protein vascular endothelial growth factor (VEGF) measured in blood and urine can predict which patients will develop acute kidney injury (AKI) after…
- Trial name
- PROVE-AKI (NCT07803328)
- Where
- Germany
- Volunteers
- 220 people
- Sponsor
- Universität Münster
Locally Advanced Breast Cancer, Triple Negative Breast Cancer
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and…
- Conditions
- Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
- Trial name
- NCT06449222
- Testing
- BNT327 Dose Level 1 (DL1), BNT327 Dose Level 1 (DL2), Nab-placlitaxel
- Where
- 31 sites in United States, Australia and 2 more
- Volunteers
- 83 people
- Sponsor
- BioNTech SE
Advanced Solid Tumor Cancer
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase…
- Trial name
- NCT04777994
- Testing
- ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Death-1 (PD-1) Inhibitor
- Where
- 30 sites in United States, France and 4 more
- Volunteers
- 248 people
- Sponsor
- Calico Life Sciences LLC
Vascular Anomaly, Generalized Lymphatic Anomaly
Identification of Biomarkers for Patients with Vascular Anomalies
The study will use blood (serum and plasma) and tissue obtained from participants undergoing prescribed surgical resection of vascular anomalies of interest proposed in this study.
- Conditions
- Vascular Anomaly, Generalized Lymphatic Anomaly, Kaposiform Hemangioendothelioma, Kaposiform Lymphangiomatosis
- Trial name
- NCT03001180
- Where
- 2 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Cholangiocarcinoma, Bile Duct Neoplasm
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
Background: Cholangiocarcinoma (CCA) is an aggressive cancer of the bile ducts. People with CCA have few treatment options and poor survival. Researchers want to see if a new drug can stop or slow CCA growth.
- Conditions
- Cholangiocarcinoma, Bile Duct Neoplasm, Biliary Tract Malignancy
- Trial name
- NCT04645160
- Testing
- Tivozanib
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Extensive-stage Small-cell Lung Cancer
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for…
- Trial name
- NCT06712355
- Testing
- Pumitamig, Atezolizumab, Etoposide
- Where
- 225 sites in United States, Australia and 12 more
- Volunteers
- 621 people
- Sponsor
- BioNTech SE
Diabetic Macular Edema (DME)
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.
- Trial name
- NCT06116916
- Testing
- KHK4951, Aflibercept Injection
- Where
- 87 sites in United States, Australia and 2 more
- Volunteers
- 185 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Non-small Cell Lung Cancer
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
This is a Phase II, multisite, open-label study consisting of two parts in participants with advanced/metastatic Non-small Cell Lung Cancer (NSCLC) which progressed after a first-line chemoimmunotherapy to evaluate the…
- Trial name
- NCT06841055
- Testing
- Pumitamig, Docetaxel
- Where
- 30 sites in United States, Australia and 4 more
- Volunteers
- 60 people
- Sponsor
- BioNTech SE
Renal Function Disorder, Diabetic Macular Edema (DME)
Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients
This study aims to investigate the impact of intravitreal injection of anti-vascular endothelial growth factor (anti VEGF) Faricimab on renal function of diabetic patients.
- Conditions
- Renal Function Disorder, Diabetic Macular Edema (DME), Neovascular Age Related Macular Degeneration
- Trial name
- NCT06929507
- Testing
- Intravitreal injection of Faricimab or Aflibercept 2 mg
- Where
- 2 sites in Greece
- Volunteers
- 60 people
- Sponsor
- University Hospital, Alexandroupolis
Recurrent Glioblastoma
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
This multi-site Phase II study will enroll adults with histologically confirmed diagnosis of World Health Organization (WHO) Grade IV glioblastoma (GBM), isocitrate dehydrogenase (IDH)-wildtype consistent with WHO central nervous…
- Trial name
- NCT07297212
- Testing
- Pumitamig, Bevacizumab, Temozolomide
- Where
- 6 sites in China
- Volunteers
- 75 people
- Sponsor
- BioNTech SE
Age-related Macular Degeneration (ARMD), Choroidal Neovascularization
Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization
Type 3 macular neovascularization (MNV) is a subtype of neovascular age-related macular degeneration accounting for 10-20% of cases, notable for high rates of bilateral involvement and risk of profound vision loss, particularly…
- Conditions
- Age-related Macular Degeneration (ARMD), Choroidal Neovascularization, Anti-vascular Endothelial Growth Factor
- Trial name
- NCT07187804
- Testing
- Intravitreal faricimab injection
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Kim's Eye Hospital
Severe Diabetic Macular Oedema
Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns
The macula is the centre of the retina; it gives central sight, colour and fine detail. People with diabetes may develop diabetic macular oedema (DMO).
- Trial name
- DAME (NCT06985706)
- Testing
- Subthreshold Micropulse Laser (SML), Anti-VEGF Monotherapy (standard care)
- Where
- 22 sites in United Kingdom
- Volunteers
- 264 people
- Sponsor
- Belfast Health and Social Care Trust
Gastrointestinal Carcinoma, Dysplasia
Study of VEGF-A Targeting NIR-II Fluorescence Endoscopy in the Gastrointestinal Tract
In this study, the investigators are studying new ways to look for abnormal tissues of the gastrointestinal tract during an endoscopy.
- Conditions
- Gastrointestinal Carcinoma, Dysplasia, Gastrointestinal Polyp
- Trial name
- NCT06430372
- Testing
- Bev-ICG, NIR-II fluorescence endoscopy platform
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Institute of Automation, Chinese Academy of Sciences
Hepatocellular Carcinoma, Immunotherapy
Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma
Through a retrospective study of patients who underwent comprehensive treatment for hepatocellular carcinoma at the Second Affiliated Hospital of Zhejiang University, we explored the risk factors related to the sensitivity of…
- Trial name
- NCT06542796
- Testing
- Immunotherapy combined with targeted therapy, Standard treatment plan
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Wet Age-related Macular Degeneration
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)
- Trial name
- DAYBREAK (NCT06556368)
- Testing
- Tarcocimab tedromer, Tabirafusp tedromer, Aflibercept
- Where
- 72 sites in United States, Puerto Rico
- Volunteers
- 667 people
- Sponsor
- Kodiak Sciences Inc
IC, Hunner Type Interstitial Cystitis
The Study is Being Conducted to Find a New Treatment for Patients Suffering From Interstitial Cystitis With Hunner's Lesions
To evaluate the efficacy and safety of Neovasculgen in interstitial cystitis with Hunner's lesions to reduce cicatricial changes in the bladder caused by electrocoagulation and to prevent secondary bladder shrinkage with a…
- Conditions
- IC, Hunner Type Interstitial Cystitis, Bladder Pain Syndrome
- Trial name
- NCT07459790
- Testing
- Neovasculgen®
- Where
- Russia
- Volunteers
- 180 people
- Sponsor
- JSC NextGen
Differentiated Thyroid Cancer
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid…
- Trial name
- NCT03690388
- Testing
- Cabozantinib
- Where
- 164 sites in United States, Argentina and 23 more
- Volunteers
- 187 people
- Sponsor
- Exelixis
Neovascular Glaucoma, Neovascularization
KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial
The clinical trial is aimed to evaluate the anti-neovascular effect of KDR2-2 suspension eyedrop in the treatment of neovascular glaucoma.
- Trial name
- KDR-NVG (NCT04844619)
- Testing
- 4mg/ml KDR2-2 suspension eyedrop, 16mg/ml KDR2-2 suspension eyedrop
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
HCC - Hepatocellular Carcinoma
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
This trial is designed to explore the efficacy and safety of interventional therapy combined with immune checkpoint inhibitors(ICIs) and anti-vascular endothelial growth factor(VEGF) antibody/tyrosine kinase inhibitors in the…
- Trial name
- NCT07157969
- Testing
- Lenvatinib, Pembrolizumab, Atezolizumab
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College Hospital
Rheumatoid Arthritis
Venlafaxine as Adjunct Therapy in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent inflammation of the joints, leading to pain, swelling, disability, and reduced quality of life.
- Trial name
- NCT07497282
- Testing
- venlafaxine extended-release (XR), Standard conventional Rheumatoid Arthritis Therapy
- Volunteers
- 70 people
- Sponsor
- Ain Shams University